Payment overview · 2025
General Payments
$546.49
29 reported records · 10 companies
Healthcare provider profile · identity verified
David J Phillips, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HIXSON, TN · NPI 1497730212
Verified facts
What the public records show
CMS Open Payments records show David J Phillips, MD received $546.49 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 35.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $196.28 | 35.9% | 11 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.20 | 12.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.38 | 12.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $67.57 | 12.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.92 | 7.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.90 | 6.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.70 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.42 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.19 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.93 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $546.49 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.77 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $154.77 | 7 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $69.20 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $67.57 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.51 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 140 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 146 |
| Gabapentin | Gabapentin | 336 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 318 | 96 |
| Omeprazole | Omeprazole | 317 | 100 |
| Lisinopril | Lisinopril | 296 | 98 |
| Metformin Hcl | Metformin Hcl | 295 | 92 |
| Prednisone | Prednisone | 232 | 163 |
| Losartan Potassium | Losartan Potassium | 227 | 76 |
| Furosemide | Furosemide | 208 | 75 |
| Carvedilol | Carvedilol | 178 | 52 |
| Montelukast Sodium | Montelukast Sodium | 174 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 52 |
| Alprazolam | Alprazolam | 154 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 48 |
| Allopurinol | Allopurinol | 147 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 48 |
| Potassium Chloride | Potassium Chloride | 144 | 49 |
| Lorazepam | Lorazepam | 143 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 22 |
| Farxiga | Dapagliflozin Propanediol | 140 | 38 |
| Pregabalin | Pregabalin | 140 | 25 |
| Simvastatin | Simvastatin | 133 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 41 |
| Tramadol Hcl | Tramadol Hcl | 123 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 35 |
| Ozempic | Semaglutide | 110 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 34 |
| Glipizide Er | Glipizide | 105 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 32 |
| Meloxicam | Meloxicam | 101 | 41 |
| Azithromycin | Azithromycin | 95 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 31 |
| Famotidine | Famotidine | 92 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 20 |
| Sertraline Hcl | Sertraline Hcl | 90 | 26 |
| Jardiance | Empagliflozin | 85 | 15 |
| Bupropion Xl | Bupropion Hcl | 80 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 32 |
| Trazodone Hcl | Trazodone Hcl | 73 | 30 |
| Celecoxib | Celecoxib | 72 | 21 |
| Metformin Hcl Er | Metformin Hcl | 72 | 25 |
| Enalapril Maleate | Enalapril Maleate | 69 | 18 |
| Glipizide | Glipizide | 68 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 15 |
| Clonazepam | Clonazepam | 58 | 11 |
| Mounjaro | Tirzepatide | 58 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 48 |
| Buspirone Hcl | Buspirone Hcl | 54 | 16 |
| Diazepam | Diazepam | 52 | suppressed |
| Spironolactone | Spironolactone | 50 | 17 |
| Donepezil Hcl | Donepezil Hcl | 49 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 14 |
| Eliquis | Apixaban | 48 | 14 |
| Amoxicillin | Amoxicillin | 46 | 35 |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Lovastatin | Lovastatin | 45 | 13 |
| Topiramate | Topiramate | 45 | 18 |
| Mirtazapine | Mirtazapine | 44 | 14 |
| Estradiol | Estradiol | 43 | 13 |
| Memantine Hcl | Memantine Hcl | 43 | 13 |
| Valsartan | Valsartan | 39 | 11 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 13 |
| Trulicity | Dulaglutide | 36 | 12 |
| Fluconazole | Fluconazole | 35 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Nabumetone | Nabumetone | 32 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 12 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 11 |
| Acyclovir | Acyclovir | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Temazepam | Temazepam | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 16 |
| Clonidine | Clonidine | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 13 |
| Mupirocin | Mupirocin | 23 | 18 |
| Alendronate Sodium | Alendronate Sodium | 22 | 11 |
| Atenolol | Atenolol | 22 | suppressed |
| Nateglinide | Nateglinide | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $546.49 · 29 records | Novo Nordisk Inc | Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error